Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAnthony S. SteinHLHannah Levavi

Discussion

Loading...

Member takes

Overview

Observational cohort study shows longer survival with tagraxofusp versus venetoclax in BPDCN, implying tag's efficacy in treatment options.

Key Points

  • To evaluate overall survival in BPDCN patients treated with tagraxofusp or venetoclax in a real-world setting.
  • Retrospective observational cohort study using US claims data
  • Included BPDCN patients starting tagraxofusp or venetoclax treatment from 2016 to 2023
  • Evaluated overall survival using Kaplan-Meier methodology
  • Matched tag and venetoclax patients 1:1 based on treatment regimen
  • Median overall survival was 35.3 months for tagraxofusp versus 10.5 months for venetoclax
  • 12-month survival rates were 72.1% for tag and 42.8% for venetoclax
  • More patients receiving tagraxofusp were able to receive subsequent lines of therapy
  • Median overall survival for monotherapy was 35.3 months for tag and 10.5 months for venetoclax

Cite This Study

Stein et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3a3https://doi.org/10.1182/blood-2025-4612
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed/refractory BPDCN.2026
  2. 2Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial2025 · 4 citations
  3. 3Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm2026 · 1 citations
  4. 4Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series2025 · 1 citations
  5. 5Real-world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm2025 · 1 citations